4 April 2011, researchers at NYU Langone Medical Center presented the study at the American Association for cancer research the 102nd Annual meeting, held in Orlando, Florida, which detailed their findings on protein test, which can be used to identify pulmonary start-up phase, related to asbestos. According to researchers test can accurately identify proteins secreted from cancer caused by asbestos.
Dr. Harvey pass, Director of the Division of thoracic surgery and Thoracic Oncology at NYU Langone Medical Center and the NYU Cancer Institute, said the Novel biomarker test that is considered the most accurate in identifying proteins secreted by tumors caused by exposure to asbestos. As a result of blinded test proteomic analysis can find 15 of the 19 cases of malignant pleural mesothelioma in stage 1 or stage 2 that makes the test about 80% sensitivity, defined as exactly test can identify the disease. Moreover the specificity of the test was 100%.
"The objective of the new diagnostic test-find cancer early enough to deal effectively with it," according to Harvey i. pass, MD.
Read the full article visit: http://communications.med.nyu.edu/news/2011/new-test-detects-early-stage-asbestos-related-pulmonary-cancer
0 comments:
Post a Comment